Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting

Schedule of reconciliation of the company's net income (loss)

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net loss in the condensed consolidated statements of operations and comprehensive loss (in thousands):

	For the Three Months Ended March 31,
	2026		2025
Direct research and development expenses by program:
TTI-101:
HCC	$	700	$	437
IPF		—		1,033
mBC		—		—
Pre-clinical, CMC, and other (unallocated) (1)		87		175
TTI-109		2,902		358
Unallocated research and development expense:
Personnel costs		1,004		858
Consultant fees and other costs (2)		218		250
General and administrative expense:
Personnel costs		932		609
Other general and administrative expenses (3)		1,208		634
Interest income		(247)		(275)
Other expense		—		5,500
Net loss	$	(6,804)	$	(9,579)

⁽¹⁾ Pre-clinical, chemistry, manufacturing and control (CMC), and other (unallocated) costs include preclinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program.

⁽²⁾ Consultant fees and other costs include expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function.

⁽³⁾ Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses.